Alvotech to Report H1 2026 Financial Results on August 19
Biotechnology company Alvotech announced it will release its financial results for the first half of 2026 on Wednesday, August 19. The company will also host a webcast with a Q&A session the following day.
REYKJAVIK, ICELAND (August 10, 2026) – Global biotechnology company Alvotech announced today that it will release its financial results for the first half of 2026 on Wednesday, August 19, after the U.S. market close. The company specializes in the development and manufacturing of biosimilar medicines.
Alvotech will also host a webcast with a live question-and-answer session on Thursday, August 20, at 8:00 AM ET. The event will provide an update on the company's financial performance and strategic direction.
The company has previously secured approvals for five biosimilars marketed in multiple global territories, targeting conditions such as autoimmune disorders, eye conditions, and osteoporosis. Alvotech aims to be a significant player in the biosimilar market through its integrated approach.
Registration is required to attend the webcast and Q&A. Presentation materials will be made available on Alvotech's website prior to the call.